ALX ONCOLOGY HOLDINGS INC appointed Jason Lettmann as new CEO

Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Announcement of New Chief Executive Officer and Chief Scientific Officer 

On September 6, 2023, ALX Oncology Holdings Inc. (the "Company") appointed Jason Lettmann, age 46 and a current member of the Company's Board of Directors (the "Board"), as the Company's Chief Executive Officer. Effective on the same date, Dr. Jaume Pons will no longer be the Company's Chief Executive Officer and will serve as the Company's Chief Scientific Officer while continuing to serve as President. 

The Company is grateful for Dr. Pons' valuable contributions to the Company over the years, and looks forward to continuing to work with him in his new role at the Company. 

Mr. Lettmann has served as a member of the Board since April 2020 and previously served as a member of the Board from March 2015 to May 2017. Mr. Lettmann has served as a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009, and served as a General Partner of Lightstone Ventures from March 2012 to July 2023. He previously served as Chief Executive Officer of Promedior Inc., a biotechnology company acquired by Roche, from January 2019 to February 2020 and as a Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB. Mr. Lettmann holds a B.A. in Psychology from the University of Iowa and an M.B.A. from the University of Michigan's Ross School of Business. The Board believes Mr. Lettmann is qualified to serve as Chief Executive Officer because of his strong executive experience and skills in executive management and his extensive industry experience. 

There are no arrangements or understandings between Mr. Lettmann and any other persons pursuant to which he was appointed Chief Executive Officer. There are no family relationships between Mr. Lettmann and any director or executive officer of the Company. 

Mr. Lettmann previously entered into an indemnification agreement on the Company's standard form, a copy of which was filed as Exhibit 10.1 to the Company's registration statement on Form S-1 (File No. 333-239490) on June 26, 2020. 

Employment Letters 

In connection with the appointment of Mr. Lettmann as the Company's Chief Executive Officer, the Company and Mr. Lettmann entered into an employment letter, effective as of September 6, 2023. Mr. Lettmann's annual base salary will be $675,000, and he will be eligible for an annual target cash incentive payment equal to 55% of his annual base salary based on achieving performance objectives established by the Board or the compensation committee of the Board, subject to continued employment through the date such annual bonus is paid. The employment letter also provides that he will be granted a stock option to purchase 1,200,000 shares of the Company's common stock under the Company's Amended and Restated 2020 Equity Incentive Plan. Given his appointment as Chief Executive Officer, Mr. Lettmann will no longer receive any separate compensation that he previously received as a non-employee director of the Board.

In connection with the appointment of Dr. Pons as the Company's Chief Scientific Officer, the Company and Dr. Pons entered into an employment letter, effective as of September 6, 2023. Dr. Pons' annual base salary will be $650,000, and he will remain eligible for an annual target cash incentive payment equal to 55% of his annual base salary based on achieving performance objectives established by the Board or the compensation committee of the Board, subject to continued employment through the date such annual bonus is paid. The employment letter also provides that any prior equity awards will continue to be subject to the terms of the applicable Company equity plan under which such equity awards were granted and the applicable award agreements thereunder. 


The foregoing descriptions of the confirmatory employment letters do not purport to be complete and are qualified in their entirety by reference to the full text of the confirmatory employment letters, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and incorporated herein by reference. 

Change in Control and Severance Agreement 

The Company and Mr. Lettmann entered into a change of control and severance agreement on the Company's standard form, a copy of which has been filed as Exhibit 10.11 to the Company's registration statement on Form S-1 (File No. 333-239490) on July 13, 2020.